Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 1

Conditions

Carcinoma, Non-Small-Cell Lung 78Squamous Cell Carcinoma of Head and Neck 43Lung Neoplasms 35Oropharyngeal Neoplasms 22Urinary Bladder Neoplasms 20Head and Neck Neoplasms 18Nasopharyngeal Carcinoma 17Carcinoma 16Biliary Tract Neoplasms 15Small Cell Lung Carcinoma 14Neoplasm Metastasis 14Cholangiocarcinoma 14Parkinson Disease 4, Autosomal Dominant Lewy Body 13Esophageal Squamous Cell Carcinoma 13Colorectal Neoplasms 13Pancreatic Neoplasms 12Neoplasms 12Uterine Cervical Neoplasms 11Carcinoma, Squamous Cell 11Ovarian Neoplasms 10Mouth Neoplasms 9Laryngeal Neoplasms 9Gallbladder Neoplasms 8Endometrial Neoplasms 8Carcinoma, Transitional Cell 8Hypopharyngeal Neoplasms 7Esophageal Neoplasms 7Triple Negative Breast Neoplasms 6Stomach Neoplasms 6Mesothelioma, Malignant 6

Interventions

Etoposide 1Cisplatin 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neuroendocrine Neoplasms × Cisplatin × 90 days × Clear all
NCT06132113 2026-05-27

DAREONâ„¢-7: A Study to Test How Well Different Doses of BI 764532 in Addition to Chemotherapy Are Tolerated by People With Advanced Neuroendocrine Cancers

Boehringer Ingelheim

Phase 1 Recruiting
55 enrolled
Endocrine

Neuroendocrine Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡